Lineage Cell Therapeutics (LCTX) Share-based Compensation (2010 - 2026)

Lineage Cell Therapeutics has reported Share-based Compensation for 17 years, with the latest figure at $1.2 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation fell 3.7% year-over-year to $1.2 million; the trailing twelve-month figure through Mar 2026 stood at $4.7 million (down 8.26% YoY), and the FY2025 full-year result was $4.8 million, down 6.4% from the prior year.
• Share-based Compensation for Q1 2026 stood at $1.2 million, up from $1.1 million in the prior quarter.
• The five-year high for Share-based Compensation was $1.3 million in Q3 2024, with the low at $959000.0 in Q4 2022.
• Historically, Share-based Compensation has averaged $1.2 million across 5 years, with a median of $1.2 million in 2025.
• Annual changes were most pronounced in 2022 — Share-based Compensation jumped 984.31% — and 2025, when it fell 16.5%.
• Lineage Cell Therapeutics' Share-based Compensation stood at $959000.0 in 2022, then increased by 10.53% to $1.1 million in 2023, then advanced by 24.06% to $1.3 million in 2024, then retreated by 16.5% to $1.1 million in 2025, then grew by 6.74% to $1.2 million in 2026.
• The last three Share-based Compensation figures came in at $1.2 million (Q1 2026), $1.1 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.